| Dr Suzanne M Allen, MD | |
|
777 N Raymond St, Boise, ID 83704-9251 | |
| (208) 367-6030 | |
| (208) 367-6123 |
| Full Name | Dr Suzanne M Allen |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 32 Years |
| Location | 777 N Raymond St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346286044 | NPI | - | NPPES |
| 805532900 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | M7741 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Full Circle Health, Inc. | 6709986797 | 93 |
| Full Circle Health, Inc. | 6709986797 | 93 |
News Archive
Nanoscientists at the Univeristy of Alicante have modified a commonly-used compound, titanium dioxide, turning it from white to black to boost its efficiency and make environmental applications a real possibility.
Impax Laboratories, Inc. today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. relating to supply of its authorized generic Adderall XR under the parties' License and Distribution Agreement that was signed in January 2006.
Virginia Commonwealth University researchers have identified a new tumor-promoting gene that may play a key role in the development of liver cancer. Levels of the gene's expression are significantly higher in more than 90 percent of patients with the disease compared to their healthy counterparts.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
One in two women in the United States will have an osteoporosis-related fracture in her lifetime. However, according to a review article published in the May 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), only a few of these women will be tested and treated for osteoporosis, which if identified and treated, could dramatically decrease their risk of future fractures.
› Verified 4 days ago
| Entity Name | Saint Alphonsus Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649357716 PECOS PAC ID: 3476462359 Enrollment ID: O20040204001036 |
News Archive
Nanoscientists at the Univeristy of Alicante have modified a commonly-used compound, titanium dioxide, turning it from white to black to boost its efficiency and make environmental applications a real possibility.
Impax Laboratories, Inc. today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. relating to supply of its authorized generic Adderall XR under the parties' License and Distribution Agreement that was signed in January 2006.
Virginia Commonwealth University researchers have identified a new tumor-promoting gene that may play a key role in the development of liver cancer. Levels of the gene's expression are significantly higher in more than 90 percent of patients with the disease compared to their healthy counterparts.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
One in two women in the United States will have an osteoporosis-related fracture in her lifetime. However, according to a review article published in the May 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), only a few of these women will be tested and treated for osteoporosis, which if identified and treated, could dramatically decrease their risk of future fractures.
› Verified 4 days ago
| Entity Name | Full Circle Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841490075 PECOS PAC ID: 6709986797 Enrollment ID: O20070924000618 |
News Archive
Nanoscientists at the Univeristy of Alicante have modified a commonly-used compound, titanium dioxide, turning it from white to black to boost its efficiency and make environmental applications a real possibility.
Impax Laboratories, Inc. today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. relating to supply of its authorized generic Adderall XR under the parties' License and Distribution Agreement that was signed in January 2006.
Virginia Commonwealth University researchers have identified a new tumor-promoting gene that may play a key role in the development of liver cancer. Levels of the gene's expression are significantly higher in more than 90 percent of patients with the disease compared to their healthy counterparts.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
One in two women in the United States will have an osteoporosis-related fracture in her lifetime. However, according to a review article published in the May 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), only a few of these women will be tested and treated for osteoporosis, which if identified and treated, could dramatically decrease their risk of future fractures.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Suzanne M Allen, MD 777 N Raymond St, Boise, ID 83704-9251 Ph: (208) 367-6030 | Dr Suzanne M Allen, MD 777 N Raymond St, Boise, ID 83704-9251 Ph: (208) 367-6030 |
News Archive
Nanoscientists at the Univeristy of Alicante have modified a commonly-used compound, titanium dioxide, turning it from white to black to boost its efficiency and make environmental applications a real possibility.
Impax Laboratories, Inc. today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. relating to supply of its authorized generic Adderall XR under the parties' License and Distribution Agreement that was signed in January 2006.
Virginia Commonwealth University researchers have identified a new tumor-promoting gene that may play a key role in the development of liver cancer. Levels of the gene's expression are significantly higher in more than 90 percent of patients with the disease compared to their healthy counterparts.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
One in two women in the United States will have an osteoporosis-related fracture in her lifetime. However, according to a review article published in the May 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), only a few of these women will be tested and treated for osteoporosis, which if identified and treated, could dramatically decrease their risk of future fractures.
› Verified 4 days ago
Dr. Maureen A Newman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-302-5480 | |
Jessica A Evert, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-7350 | |
Tracy Adams, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 777 N Raymond St, Boise, ID 83704 Phone: 208-514-2500 | |
Sarah A Hershman, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 777 N Raymond St, Boise, ID 83704 Phone: 208-514-2500 Fax: 208-375-2217 | |
Summer E Szumski, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 777 N Raymond St, Boise, ID 83704 Phone: 208-514-2500 Fax: 208-375-2217 | |
Dr. Thornton E Bryan Iii, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E Parkcenter Blvd, Boise, ID 83706 Phone: 208-381-6500 Fax: 208-381-6505 | |
Irvin E Sackman Jr., MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 130 E Boise Ave, Boise, ID 83706 Phone: 208-345-4066 Fax: 208-345-4196 |